Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2011 Results
Date:8/4/2011

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2011.

"We are pleased with our progress towards our vision of building a CNS specialty pharmaceutical company.  Fanapt® scripts in the U.S. continued to grow, and we have made advances towards the globalization of the franchise.  We are excited about the prospects of our tasimelteon programs in both Non-24 and major depression, which are currently underway," said Mihael Polymeropoulos, M.D., President and Chief Executive Officer.

Key Highlights:

  • Vanda recorded second quarter 2011 revenue of $7.4 million including royalties of $0.8 million. Second quarter sales of Fanapt® as reported by Novartis included a $2.7 million cumulative adjustment to gross to net sales reserves that resulted in approximately $270 thousand less in royalties to Vanda in the period.
  • Fanapt® prescriptions, as reported by IMS, reached 30,000 in the second quarter of 2011.  This represents a 17% increase over first quarter 2011 prescriptions.  
  • On July 22, 2011, the European Medicines Agency (EMA) notified Vanda that it had accepted for evaluation the Marketing Authorization Application (MAA) for oral iloperidone tablets.
  • Vanda announced commercialization agreements for two Latin American markets.  On July 11, 2011, Vanda entered into an exclusive license agreement with Probiomed S.A. de C.V. (Probiomed) for the commercialization of Fanapt® in Mexico.   On August 1, 2011, Vanda entered into an exclusive license agreement with Biotoscana Farma S.A. (Biotoscana
    '/>"/>

  • SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
    (Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
    (Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    ... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
    ... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
    Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
    (Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
    (Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
    (Date:4/18/2014)... Diego, Calif. (April 18, 2014) ― A new study ... analyzing weekly patterns in health-related Google searches reveals a ... health strategies. , Investigators from San Diego ... and the Monday Campaigns, analyzed "healthy" Google searches (searches ... e.g., "healthy diet") originating in the U.S. from 2005 ...
    (Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
    (Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
    Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
    ... ... Hospital Association’s (MHA) Quality Indicator Project® has signed an agreement with ... solution with 3M™ ClinTrac™ Quality Manager Software. The joint solution ... analytical tools, and comparative reports in an integrated system, allowing hospitals ...
    ... new national survey on public attitudes toward medical applications ... support for the technology increases when the public is ... benefits at least among those people who have ... researchers at North Carolina State University and Arizona State ...
    ... researchers at Columbia University,s Mailman School of Public Health ... genes, altering their functions and leading to the development ... suggest a new biological model of PTSD in which ... a person,s stress response and leads to the disorder," ...
    ... NY MAY 4, 2010 TCT for Surgeons ... techniques in the field that are improving outcomes for ... the course will run during Transcatheter Cardiovascular Therapeutics (TCT) ... Cardiovascular Research Foundation. "This meeting will drive forward ...
    ... ... County, Maryland offer convenient access to the Baltimore/Washington metropolitan areas—without the high costs. ... Hagerstown, MD (PRWEB) ... the nation’s leading biotech convention, but the Hagerstown-Washington County Economic Development Commission will be ...
    ... ... websites to businesses looking to grow through seo services. The Atlanta SEO Company offers this ... ... put a strain on many marketing budgets in the Atlanta metro area. We all know ...
    Cached Medicine News:Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 2Health News:3M and Maryland Hospital Association's Quality Indicator Project Partner to Deliver Comprehensive Quality Solution 3Health News:Survey: Hiding risks can hurt public support for nanotechnology 2Health News:Trauma-induced changes to genes may lead to PTSD 2Health News:Western Maryland to be Featured at BIO International Convention 2Health News:Western Maryland to be Featured at BIO International Convention 3Health News:Western Maryland to be Featured at BIO International Convention 4Health News:Atlanta SEO Company Offers Free Websites to Help Businesses Grow Again in the Tough Economy 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: